- Home
- PCYO vs BCYC Comparison
PCYO vs BCYC Comparison
Compare PCYO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | BCYC |
|---|---|---|
| Founded | 1976 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.1M | 291.8M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCYO | BCYC |
|---|---|---|
| Price | $10.95 | $3.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 69.3K | ★ 475.4K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.71 | $3.33 |
| 52 Week High | $12.44 | $9.08 |
Technical Indicators
Market Signals| Indicator | PCYO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 46.93 |
| Support Level | $10.67 | $3.33 |
| Resistance Level | $11.03 | $4.07 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 39.68 | 43.74 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.